Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates
June 15 2022 - 7:55AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, today published new data from oncology clinical
research executives, indicating three-quarters of all planned new
oncology study starts over the next 12 months will include elements
of decentralization.
Globally, there are already more than 3,7001 active oncology
clinical trials, with research and development spending projected
to top US$70 billion2 in 2022 alone—accounting for around
one-third3 of all drug R&D budgets this year. According to
projections, by 2026, we could see more than 10,5004 oncology
clinical trials.
“We are experiencing increased adoption of decentralization in
the oncology space,” said Dr. Shaalan Beg, Vice President,
Oncology, Science 37, and co-author of the report How Agile
Clinical Trials are Impacting Oncology Research. “Oncology studies
are often challenging for patients who suffer from cancer and
treatment side effects. By providing a more agile approach to
oncology trial design, we can present patients with more
flexibility to participate without the burden of travel and wasted
time in a waiting room.”
To explore current dynamics and future trends in oncology
clinical trial design, Science 37 undertook a global survey of
clinical research executives in the oncology space. The study was
conducted in March and April of 2022.
“Putting the patient first is a key trend across sponsors and
CROs conducting oncology clinical trials—much like in CNS and
across all therapeutic areas,” said Drew Bustos, Chief Strategy
Officer, Science 37, and co-author of the report. “Providing a more
agile clinical trial design provides a more equitable healthcare
landscape by reducing the burden of clinical trial participation
and enabling universal access for patients and providers,
anywhere.”
Among the findings:
- Almost three-quarters of oncology executives (73%) are planning
to run either an agile (hybrid) or fully decentralized clinical
trial in the next 12 months, up from just half (49%) in the
previous 12 months.
- The biggest perceived challenges with traditional oncology
clinical trials (including both traditional studies and agile/DCTs)
are Patient Recruitment (72% of execs ranked it in their top
three), Study Start-Up (55%), and Timeline/Delays (54%).
- The top three perceived benefits of using agile/DCT tools in
oncology trials are Increased Patient Retention (which 67% of
respondents ranked in their top three), Greater Patient Diversity
(54%), and Faster Patient Recruitment (50%).
You can download your complimentary copy of the full report at
https://www.science37.com/oncologyreport.
Source1, 2, 3, 4 Evaluate Pharma
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 l Operating System (OS) supports
today’s more agile clinical research designs with its full-stack,
end-to-end technology platform and centralized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators, provider communities, and data and devices.
Configurable to enable almost any study type, the Science 37 OS
enables up to 21x faster enrollment, 28% better retention, and 3x
more diverse patient population with industry-leading workflow
orchestration, evidence generation, and data harmonization. For
more information, visit
https://www.science37.com.
MEDIA INQUIRIES:Drew Bustospr@science37.com610.
417.6953
INVESTOR RELATIONS:Caroline
Paulinvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024